Amgen, J&J planning Kyprolis-Darzalex combo studies
Amgen Inc. (NASDAQ:AMGN) and the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to evaluate combinations of Amgen's Kyprolis carfilzomib and Janssen’s Darzalex daratumumab to treat multiple myeloma and other cancers. Amgen said the partners plan to start enrolling their first Phase III study in April 2017. Janssen said the partnership covers all potential opportunities for the combination in oncology.
Amgen is to sponsor the first Phase III trial, which will test the combination plus dexamethasone vs. Kyprolis plus dexamethasone in MM patients who have had one to three prior lines of therapy. Amgen said the partners will elect on a study-by-study basis whether to share development costs of each planned trial. Amgen spokesperson Kristen Davis declined to provide further financial terms...
BCIQ Target Profiles